简介:everyonehasitsownweeklyplan.Allthepeopledotheirworkaccordingtotheplan.Throughplanandgoalmanagement,theShenyangenvironmentalprotectionbureaustartedtocarryouttheplanandthegoalmanagementfrom2001.Totheoverallsituationworkformulationdetailedtotalplanandtheconcreteactionprogram,TheShenyangenvironmentalprotectionbureauistheShenyangmuinicplegovernmentenvironmentalprotectionadministrativedepartment
简介:这研究的目的是评估crosslinking效果一自然地bioprosthetic心阀门的材料上的crosslinkingreagent-procyanidins(PA)。在由procyanidins修理牛的心囊的纸巾以后,crosslikng特征,机械性质,在vitro,酶的降级抵抗,hydrophilicity和溶血测试被检验。结果证明有glutaraldehyde(GA)或procyanidins的生物织物的固定象在vitro一样增加了它的变性作用温度,表面hydrophilicity和机械性质酶的降级抵抗。在变性作用温度没有重要差别,机械性质,hydrophilicity并且在里面在glutaraldehyde和procyanidins之间的酶的降级修理了的vitro纸巾。然而,procyanidins的最终的张力的力量修理了纸巾比glutaraldehyde显著地优异固定纸巾。溶血测试证明procyanidins的那溶血率修理了纸巾比glutaraldehyde的修理纸巾的低。这研究显示出那个procyanidins罐头交叉连接它牛的pericardiaa有效地没有毒性。我们的结果建议这个方法可能是为bioprosthetic心阀门的准备的一条有用途径。
简介:Withtherapidgrowthoftheinternet,thefastinformationcommunicationandthecomprehensiveinformationpublicationbecomeavailable.Toattracttheattentionofbrowsersandletbrowsersknowthehotnewsintime,awebsiteisrequiredtoupdateitscontentconstantly.Thetraditionalmodetomanuallyupdatewebsiteisnolongersuitablefortherapidgrowthofwebsitecontents.Moreover,
简介:Objective:Estimationofactivityaccumulatedintumorandorgansisveryimportantinpredictingtheresponseofradiopharmaceuticalstreatment.Inthisstudy,wesynthesized177Lutetium(177Lu)-trastuzumabironoxidenanoparticlesasadoubleradiopharmaceuticalagentfortreatmentandbetterestimationoforganactivityinanewwaybymagneticresonanceimaging(MRI).Methods:177Lu-trastuzumab-ironoxidenanoparticlesweresynthesizedandallthequalitycontroltestssuchaslabelingyield,nanoparticlesizedetermination,stabilityinbufferandbloodserumupto4d,immunoreactivityandbiodistributioninnormalmiceweredetermined.Inmicebearingbreasttumor,liverandtumoractivitieswerecalculatedwiththreemethods:singlephotonemissioncomputedtomography(SPECT),MRIandorganextraction,whichwerecomparedwitheachother.Results:Thegoodresultsofqualitycontroltests(labelingyield:61%±2%,meannanoparticlehydrodynamicsize:41±15nm,stabilityinbuffer:86%±5%,stabilityinbloodserum:80%±3%,immunoreactivity:80%±2%)indicatedthat177Lu-trastuzumab-ironoxidenanoparticlescouldbeusedasadoubleradiopharmaceuticalagentinmicebearingtumor.Resultsshowedthat177Lu-trastuzumab-ironoxidenanoparticleswithMRIhadtheabilitytomeasureorganactivitiesmoreaccuratethanSPECT.Conclusions:Co-conjugatingradiopharmaceuticaltoMRIcontrastagentssuchasironoxidenanoparticlesmaybeagoodwayforbetterdosimetryinnuclearmedicinetreatment.